For research use only. Not for therapeutic Use.
GSK-2334470（Cat No.:I000880）is a highly selective small-molecule inhibitor of 3-phosphoinositide-dependent protein kinase 1 (PDK1), a key regulator in the PI3K/Akt signaling pathway. PDK1 plays a crucial role in activating Akt and other AGC kinases, which are involved in cell survival, growth, and metabolism. By inhibiting PDK1, GSK-2334470 blocks downstream signaling, making it a valuable compound for research in cancer and metabolic disorders. Its specificity allows for detailed studies of PDK1’s function, helping to explore therapeutic approaches targeting hyperactive PI3K/Akt pathways in oncogenesis and other diseases.
| Catalog Number | I000880 |
| CAS Number | 1227911-45-6 |
| Synonyms | (3S,6R)-1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)pyrimidin-4-yl]-N-cyclohexyl-6-methylpiperidine-3-carboxamide |
| Molecular Formula | C₂₅H₃₄N₈O |
| Purity | ≥95% |
| Target | PDK-1 |
| Solubility | 10 mM in DMSO |
| Storage | 2-8°C |
| IC50 | 10 nM |
| IUPAC Name | (3S,6R)-1-[6-(3-amino-1H-indazol-6-yl)-2-(methylamino)pyrimidin-4-yl]-N-cyclohexyl-6-methylpiperidine-3-carboxamide |
| InChI | InChI=1S/C25H34N8O/c1-15-8-9-17(24(34)28-18-6-4-3-5-7-18)14-33(15)22-13-20(29-25(27-2)30-22)16-10-11-19-21(12-16)31-32-23(19)26/h10-13,15,17-18H,3-9,14H2,1-2H3,(H,28,34)(H3,26,31,32)(H,27,29,30)/t15-,17+/m1/s1 |
| InChIKey | QLPHOXTXAKOFMU-WBVHZDCISA-N |
| SMILES | C[C@@H]1CC[C@@H](CN1C2=NC(=NC(=C2)C3=CC4=C(C=C3)C(=NN4)N)NC)C(=O)NC5CCCCC5 |
| Reference | </br>1:PDK1 inhibitor GSK2334470 exerts antitumor activity in multiple myeloma and forms a novel multitargeted combination with dual mTORC1/C2 inhibitor PP242. Yang C, Huang X, Liu H, Xiao F, Wei J, You L, Qian W.Oncotarget. 2017 Mar 29. doi: 10.18632/oncotarget.16642. [Epub ahead of print] PMID: 28402933 Free Article</br>2:Characterization of GSK2334470, a novel and highly specific inhibitor of PDK1. Najafov A, Sommer EM, Axten JM, Deyoung MP, Alessi DR.Biochem J. 2011 Jan 15;433(2):357-69. doi: 10.1042/BJ20101732. PMID: 21087210 |
